FreeCME

Improving Outcomes and Quality of Life in Beta-Thalassemia: Patient Perspectives and Expert Recommendations

/ Print /
| ShareMore
/ Text Size +
12/10/21 3:00 pm EDT
Hyatt Regency Atlanta + Live Streaming


The Improving Outcomes and Quality of Life in Beta-Thalassemia: Patient Perspectives and Expert Recommendations is not to be missed!

Beta-thalassemia is caused by 1 or more mutations in the beta globin gene, and patients with differing mutant phenotypes can develop 1 of several varieties of thalassemia, including thalassemia major, which is the most severe form. Thalassemia major presents within the first 2 years of life, with blood transfusions required for survival. Other therapies include stimulation of fetal hemoglobin production, transplantation of bone marrow, hematopoietic stem cell transplantation, and gene therapy. All of these options present advantages and risks to the patient.

Learning Objectives

The learning objectives of this program are:

  • Assess unmet needs in the management of beta-thalassemia and rationale supporting the role of novel therapeutic strategies
  • Describe recent landmark evidence utilizing novel approaches for the management of beta-thalassemia and how new strategies can be practically applied to clinical practice
  • Examine mechanistic rationale as well as key efficacy and safety data on emerging therapies and strategies in the management of patients with beta-thalassemia
  • Identify patients with beta-thalassemia who may benefit from clinical trial participation evaluating emerging therapies and/or strategies

Date

December 10, 2021

Registration and Lunch: 2:15 PM – 3:00 PM

Scientific Session: 3:00 PM – 5:00 PM EST

 

Program Chair

Thomas D. Coates, MD
Section Head, Hematology
Cancer and Blood Disease Institute
Professor of Pediatrics and Pathology
University of Southern California Keck School of Medicine
Childrens Hospital Los Angeles
Los Angeles, CA